Shots:

• Grifols to acquire the remaining stock of Alkahest for a total value of $146M. The transaction is expected to be close in H1’21
• The acquisition will enhance discovery- research- development to identify innovative therapies for age-related diseases based upon an understanding of the human plasma proteome
• Alkahest has developed a map of the human plasma proteome facilitating the identification of plasma proteins and their recombinant analogs as therapies and has four candidates in six P-II studies targeting cognitive decline- neuromuscular and ophthalmic indications

Click here ­to­ read full press release/ article | Ref: Grifols | Image: Alkahest